hCRBN

Nomenclature

C57BL/6Smoc-Crbntm1(hCRBN)Smoc

Cat. NO.

NM-HU-225071

Strain State

Repository Live

Export PDF

Model Description

The endogenous mouse Crbn gene was replaced by human CRBN gene.

Validation Data

image.png

Fig.1 Detection of CRBN expression in spleen, brain, liver, intestine and muscle tissues by RT-PCR. 

Wild type: only one band at 185 bp with primers F1/R1 (mCrbn);

Homozygous: one band at 262 bp with primers F2/R2 (hCRBN) and one band at 374 bp with primers F3/R3 (hCRBN);

Abbr. M, DNA marker; HO, homozygous;  WT, wild type.

image.png

Fig.2 Expression characterization of hCRBN in homozygous hCRBN KI mice by Western blot.

image.png

Fig. 3 The degradation of GSPT1, CK1a and Myc by Lenalidomide and CC-885 in hCRBN knockin mice were determined by western blot.

The splenocytes derived from wild-type C57BL/6 (WT) and homozygous hCRBN KI (HO) mice were treated with 1% DMSO, Lenalidomide (10 nM, 100 nM, 1000 nM) and CC-885 (10 nM, 100 nM, 1000 nM) ,respectively, in RPMI-1640 cell culture medium for 18 hours ex vivo.

image.png

Fig.4 Blood concentration curves of Lenalidomidein in C57BL/6 and HO hCRBN mice (female, 10wks, n=3).

(In cooperation with a client)

image.png

Fig.5 Blood concentration of CC-885 in C57BL/6 and  hCRBN mice 1h after first administration (female, 10wks). (In cooperation with a client)

image.png

Fig.6 Mean body weight (A) and survival curve (B) of C57BL/6 and HO hCRBN KI mice treated with CC-885 or vehicle (n=8/group). 

All hCRBN mice treated with CC-885 dead within 2 days, while mice from other groups survived. The result indicates that CC-885 exhibits significant toxicity only in hCRBN humanized mice (In cooperation with a client).

image.png

Fig.7 The degradation of GSPT1, CK1a and Myc by CC-885 in C57BL/6 and hom hCRBN knockin mice in vivo (In cooperation with a client).

The wild-type C57BL/6 (WT, group 1&2) and homozygous hCRBN KI (HO, group 3&4) mice were treated with vehicle (group 1&3)  and 5 mg/kg CC-885 (group 2&4) , respectively. The mice were anesthetized, perfused, and tissues were harvested at 6 hr post the 2nd administration.

image.png

Fig.8 Partial representative pictures of small intestine pathology (Magnification: 200x).

(In cooperation with a client)

image.png

Fig.9 Partial representative pictures of liver pathology (Magnification: 200x).

(In cooperation with a client)

image.png

Fig.10 Partial representative pictures of spleen pathology (Magnification: 200x).

(In cooperation with a client)


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Learn more